The antiplatelet effects of ticlopidine and clopidogrel

Annals of Internal Medicine

Volumn 129, Issue 5, 1998, Pages 394-405

  Sharis, Peter J ^a,b   Cannon, Christopher P ^a,b   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; CORONARY ARTERY BYPASS SURGERY; DRUG INDICATION; DRUG MECHANISM; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY FAILURE; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SKIN DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 0032168873     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-5-199809010-00009     Document Type: Review

References (142)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-94.
2. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
3. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein Ilb/Illa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-9.
4. Moliterno DJ, Topol EJ. Meta-analysis of platelet GP Ilb/Illa antagonist randomized clinical trials in ischemic heart disease: consistent, durable salutary effects [Abstract]. Circulation. 1997:96(Suppl I):I-475.
5. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856-84.
6. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet. 1994;26:347-55.
7. Teitelbaum P. Pharmodynamics and pharmacokinetics of ticlopidine. In: Haas WK, Easton JD, eds. Ticlopidine, Platelets, and Vascular Disease. New York: Springer-Verlag, 1993:27-40.
8. Harbison JW. Ticlopidine hydrochloride. In: Messerli FH. Cardiovascular Drug Therapy. Philadelphia: WB Saunders: 1996:1465-73.
9. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs. 1987;34:222-62.
10. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430-6.
11. Schafer AI. Antiplatelet therapy. Am J Med. 1996;101:199-209.
12. David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res. 1993;14:35-49.
13. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993;11:180-98.
14. Feliste R, Delebassee D, Simon MF, Chap H, Defreyn G, Vallee E, et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987;48:403-15.
15. Hardisty RM, Powling MJ, Nokes TJ. The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost. 1990;64:145-50.
16. Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532-43.
17. Gachet C, Stierle A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein Ilb-Illa complex in rat and in man. Biochem Pharmacol. 1990;40: 229-38.
18. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985;75:328-38.
19. Meyer D, Pietu G, Fressinaud E, Girma JP. von Willebrand factor: structure and function. Mayo Clin Proc. 1991;66:516-23.
20. Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol. 1995;91:434-44.
21. Hourani SM, Hall DA. Receptors for ADP on human blood platelets. Trends Pharmacol Sci. 1994;15:103-8.
22. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998;422:291-5.
23. 1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186-90.
24. 1. Biochem Pharmacol. 1990; 40:2683-7.
25. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997;54:745-50.
26. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al. Sustained platelet glycoprotein Ilb/Illa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation. 1997;96:1117-21.
27. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet Ilb/Illa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-42.
28. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol. 1993;22:381-9.
29. Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. The interactions of ticlopidine and aspirin in normal subjects. J Int Med Res. 1977;5:405-11.
30. Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, et al. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke. 1989;20:1643-7.
31. Darius H, Veit K, Rupprecht HJ. Synergistic inhibition of platelet aggregation by ticlopidine plus aspirin following intracoronary stent placement [Abstract]. Circulation. 1996;94(Suppl I):I-257.
32. Harker LA, Bruno JJ. Ticlopidine's mechanism of action on platelets. In: Hass WK, Easton JD, eds. Ticlopidine, Platelets, and Vascular Disease. New York: Springer-Verlag; 1993:41-59.
33. Gryglewski RJ, Korbut R, Swies J, Kostka Trabka E, Bieron K, Robak J. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol. 1996;308:61-7.
34. Preiss JP, Lecompte T, Alnot Y, Colin AM, Mazzi C, Angioi M, et al. Serial antiplatelet effects of combined treatment of ticlopidine and aspirin after stent implantation [Abstract]. Circulation. 1996;94(Suppl I):I-685.
35. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation. 1996;94:279-85.
36. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb. 1993;13:393-7.
37. Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, et al. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost. 1994;71:655-62.
38. Makkar R, Eigler N, Kaul S, Zeng H, Herbert JM, Litvack F. Clopidogrel, a novel platelet ADP-receptor antagonist inhibits aspirin and ticlopidine-resistant stent thrombosis [Abstract]. J Am Coll Cardiol. 1997;29(Suppl A): 353A.
39. Makkar R, Litvack F, Kaul S, Zeng H, Eigler N. High shear overrides the antithrombotic effects of aspirin on stent thrombosis [Abstract]. J Am Coll Cardiol. 1997;29(Suppl A):354A.
40. Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: a review. Semin Thromb Hemost. 1989;15:159-66.
41. Tanahashi N, Fukuuchi Y, Tomita M, Matsuoka S, Takeda H. Ticlopidine improves the enhanced erythrocyte aggregability in patients with cerebral infarction. Stroke. 1993;24:1083-6.
42. Fagher B, Persson S, Persson G, Larsson H. Blood viscosity during long-term treatment with ticlopidine in patients with intermittent claudication. A double-blind study. Angiology. 1993;44:300-6.
43. Randi ML, Fabris F, Crociani ME, Battocchio F, Girolami A. Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease. Arzneimittelforschung. 1985;35:1847-9.
44. Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol. 1982; 35:740-3.
45. Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke. 1994;25:2017-21.
46. Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemost. 1985;54: 808-12.
47. Carrieri P, Orefice G, Fioretti A, Indaco A, Carfagna S. Effects of long-term ticlopidine treatment and platelet function and its tolerability in cerebrovascular disease. J Int Med Res. 1984;12:286-91.
48. Kirstein P, Jogestrand T, Johnsson H, Olsson AG. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis. 1980;36:471-80.
49. Gent M, Blakely JA, Easton JO, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-20.
50. Mass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321:501-7.
51. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Stroke. 1993;24:1452-7.
52. Bergamasco B, Benna P, Carolei A, Rasura M, Rudelli G, Fieschi C. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Funct Neurol. 1997;12:33-43.
53. Guidelines for medical treatment for stroke prevention. American College of Physicians. Ann Intern Med. 1994;121:54-5.
54. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-8.
55. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988;39:802-11.
56. Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol. 1993;35:523-8.
57. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation. 1990;82:17-26.
58. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348: 1329-39.
59. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334:1084-9.
60. Ferguson JJ, Fox R. Meeting highlights. The 69th Scientific Sessions of the American Heart Association in New Orleans, LA, November 10-13, 1996. Circulation. 1997;95:761-4.
61. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-22.
62. Chevigne M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg. 1984;37:371-8.
63. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg. 1987;94:773-83.
64. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med. 1997;337:1726-31.
65. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. Arch Ophthalmol. 1990;108:1577-83.
66. Gent M. Benefit of clopidogrel in patients with coronary artery disease [Abstract]. Circulation. 1997:96(Suppl I):I-467.
67. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and outcome. J Am Coll Cardiol. 1997;29:6-12.
68. Hasdai D, Garratt KN, Holmes DR Jr, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol. 1996;28:361-7.
69. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis evolving issues and current concepts. J Am Coll Cardiol. 1996;27:494-503.
70. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-6.
71. Wong SC, Baim DS, Schatz RA, Teirstein PS, King SB 3d, Curry RC Jr, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol. 1995;26: 704-12.
72. Eeckhout E, Kappenberger L, Goy JL. Stents for intracoronary placement: current status and future directions. J Am Coll Cardiol. 1996;27:757-65.
73. Bittl JA. Advances in coronary angioplasty. N Engl J Med. 1996;335:1290-302.
74. Bailey SR, Kiesz RS. Intravascular stents: current applications. Curr Probl Cardiol. 1995;20:614-78.
75. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF. et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13-7.
76. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-95.
77. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991;83:148-61.
78. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
79. More RS, Chauhan A. Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet. 1997;349:146-7.
80. Karrillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94:1519-27.
81. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-88.
82. Goldberg SL, Colombo A, Maiello L, Borrione M, Find L, Almagor Y. Intracoronary stent insertion after balloon angioplasty of chronic total occlusions. J Am Coll Cardiol. 1995;26:713-9.
83. Nakamura S, Hall P, Gaglione A, Tiecco F, Di Maggio M, Maiello L, et al. High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation. J Am Coll Cardiol. 1997;29:21-7.
84. Dirschinger J, Schuhlen H, Walter H, Hadamitzky M, Zitzmann EM, Wehinger A, et al. Intracoronary stenting and antithrombotic regimen trial: one-year clinical follow-up [Abstract]. Circulation. 1997:94(Suppl I):I-257.
85. Goods CM, Al-Shaibi KF, Liu MW, Yadav JS, Mathur A, Jain SP, et al. Comparison of aspirin alone versus aspirin and ticlopidine after coronary artery stenting. Am J Cardiol. 1996;78:1042-4.
86. Albiero R, Hall P, Itoh A, Blengino S, Nakamura S, Martini G, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation. 1997;95:1145-56.
87. Machraoui A, Germing A, von Dryander S, Grewe PH, Jager D, Bojara W, et al. Efficacy and safety of ticlopidine and aspirin in post-stenting medical treatment: results of a randomized clinical trial [Abstract]. Circulation. 1997:96(Suppl I):I-593-4.
88. Barragan P, Sainsous J, Silvestri M, Simeoni JB, Bayet G, Roquebert PO, et al. Coronary artery stenting without anticoagulation, aspirin, ultrasound guidance, or high balloon pressure: prospective study of 1,051 consecutive patients. Cathet Cardiovasc Diagn. 1997;42:367-73.
89. Roy PR, Lowe HC, Walker BW, Baron DW, Gavaghan TP, Morgan JJ. Intracoronary stenting without intravascular ultrasound guidance followed by antiplatelet therapy with aspirin alone in selected patients. Am J Cardiol. 1996;77:1105-7.
90. Schuhlen H, Hadamitzky M, Walter H, Blasini R, Ulm K, Schomig A. Particular benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary stent placement. Analysis of a prospective risk stratification protocol in the ISAR trial [Abstract]. Circulation. 1996; 94(Suppl I):I-257.
91. Machraoui A, Germing A, von Dryander S, Jager D, Lemke B, Lange S, et al. Is the treatment regimen with Coumadin plus aspirin or aspirin alone obsolete after high pressure coronary stenting? In-hospital and follow up results of a randomized study [Abstract]. Circulation. 1997;94(Suppl I):I-256.
92. Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29: 13-20.
93. vom Dahl J, Klues HG, Reffelamann T, Hendricks F, Hanrath P. Combined antiplatelet pretreatment with aspirin and ticlopidine reduces in-hospital cardiac events following elective coronary angioplasty [Abstract]. J Am Coll Cardiol. 1997:29(Suppl A):98A.
94. Russo RJ, Lucisiano JE, Anderson E, Anderson J, Norman S, Stevens KM, et al. Angiographic and clinical predictors of stent thrombosis after ticlopidine therapy: observations from the STAT Multicenter Registry [Abstract]. Circulation. 1997:94(Suppl I):I-654.
95. Kataoka K, Sato Y, Ito H, Takatsu Y. Palmaz-Schatz stent implantation with 10 days ticlopidine treatment [Abstract]. Circulation. 1996:94(Suppl I):I-684.
96. Berger PB, Melby SJ, Grill DE, Bell MR. How long should ticlopidine be administered to intracoronary stent patients not treated with Coumadin? [Abstract] Circulation. 1996;94(Suppl I):I-256.
97. Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28:1444-51.
98. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3d, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337:740-7.
99. Piana RN, Moscucci M, Cohen DJ, Kugelmass AD, Senerchia C, Kuntz RE, et al. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome. J Am Coll Cardiol. 1994;23: 1296-304.
100. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol. 1996;28:89-96.
101. Garcia-Cantu E, Spaulding C, Corcos T, Hamda KB, Roussel L, Favereau X, et al. Stent implantation in acute myocardial infarction. Am J Cardiol. 1996;77:451-4.
102. Le May MR, Labinaz M, Beanlands RS, Laramee LA, O'Brien ER, Marquis JF, et al. Usefulness of intracoronary stenting in acute myocardial infarction. Am J Cardiol. 1996;78:148-52.
103. Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Coronary stenting after unsuccessful emergency angioplasty in acute myocardial infarction: results in a series of consecutive patients. Am Heart J. 1996;132:1115-8.
104. Schomig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, Zitzmann-Roth EM, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulation therapy. J Am Coll Cardiol. 1997;29:28-34.
105. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St Goar FG, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI Stent Pilot Trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol. 1998;31:23-30.
106. Valeix BH, Labrunie PJ, Massiani PF. Systematic coronary stenting in the first eight hours of acute myocardial infarction [Abstract]. Circulation. 1996; 94(Suppl I):I-577.
107. Leon MB, Ellis SG, Moses J, King SB 3d, Heuser R, Kent KM, et al. Interim report from the Reduced Anticoagulation VEin Graft Stent (RAVES) study [Abstract], J Am Coll Cardiol. 1997:29(Suppl A):683A.
108. Lablanche JM, Gauthier L, McFadden EP, Grollier G, Bauters C, Bonnet JL, et al. In-hospital and six month outcome after bailout stenting managed with antiplatelet therapy alone [Abstract]. Circulation. 1996; 94(Suppl I):I-684.
109. Itoh A, Hall P, Maiello L, Di Mario C, Moussa I, Blengino S, et al. Intracoronary stent implantation in native coronary arteries and saphenous vein grafts: a consecutive experience with six types of stents without prolonged anticoagulation. Mayo Clin Proc. 1997;72:101-11.
110. Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent II Pilot Study. Circulation. 1996;93:412-22.
111. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-703.
112. Manolis AS, Vassilikos V, Maounis TN, Psarros L, Melita-Manolis H, Papatheou D, et al. Pretreatment with aspirin and ticlopidine confers lower thrombogenic potential of radiofrequency catheter ablation. Am J Cardiol. 1997;79:494-7.
113. Cerisier A, Isaaz K, Dacosta A, Venet C, De Pasquale JP, Lamaud M. Prevention of reocclusion after successful balloon PTCA of totally occluded coronary arteries: a prospective randomized pilot-study comparing ticlopidine-aspirin association with aspirin alone [Abstract]. J Am Coll Cardiol. 1997;29(Suppl A):395A.
114. Chotinaiwattarakul C, Mahanonda N, Kangkagate C, Chaithiraphan S. Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA). J Med Assoc Thai. 1997;80:76-80.
115. Wysowski DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [Letter]. JAMA. 1996;276:952.
116. Molony BA. An analysis of the side effects of ticlopidine. In: Haas WK, Easton JD, eds. Ticlopidine, Platelets, and Vascular Disease. New York: Springer-Verlag; 1993:117-39.
117. McTavish D, Faulds D, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs. 1990;40:238-59.
118. Shear NH, Appel C. Prevention of ischemic stroke [Letter]. N Engl J Med. 1995;333:460.
119. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337:774-6.
120. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke. 1992;23:922-3.
121. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother. 1993;27:1060-1.
122. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis [Letter]. Am J Hematol. 1997;54:175-6.
123. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura [Letter]. N Engl J Med. 1997;337:1245.
124. Sheffield JV, Merrens E. More about thrombotic thrombocytopenic purpura. N Engl J Med. 1998;338:548.
125. Ben nett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998;128:541-4.
126. Takishita S, Kawazoe N, Yoshida T, Fukiyama K. Ticlopidine and thrombocytopenia [Letter]. N Engl J Med. 1990;323:1487-8.
127. Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Hematol. 1997;98:211-3.
128. Yen SP, Hsueh EJ, Wu H, Wang YC. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol. 1998;76:87-90.
129. Naschitz JE, Khamessi R, Elias N, Yeshurun D. Ticlopidine-induced prolonged cholestasis [Letter]. J Toxicol Clin Toxicol. 1995;33:379-80.
130. Grimm IS, Litynski JJ. Severe cholestasis associated with ticlopidine. Am J Gastroenterol. 1994;89:279-80.
131. Ruiz-Valverde P, Zafon C, Segarra A, Ribera R, Piera L. Ticlopidine-induced granulomatous hepatitis [Letter]. Ann Pharmacother. 1995;29:633-4.
132. Rosen H, el-Hennawy AS, Greenberg S, Chen CK, Nicastri AD. Acute interstitial nephritis associated with ticlopidine. Am J Kidney Dis. 1995;25: 934-6.
133. Elsman P, Zijlstra F. Ticlopidine and renal function [Letter]. Lancet. 1996; 348:273-4.
134. Shah J, Fratis A, Ellis D, Murakami S, Teitelbaum P. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol. 1990;30:733-6.
135. Birmele B, Lebranchu Y, Bargos P, Nivet H, Furet Y, Pengloan J. Interaction of cyclosporin and ticlopidine [Letter]. Nephrol Dial Transplant. 1991;6:150-1.
136. Boissonnat P, de Lorgeril M, Perroux V, Salen P, Batt AM, Barthelemy JC, et al. A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients. Eur J Clin Pharmacol. 1997;53:39-45.
137. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41:358-62.
138. Brown RI, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol. 1997;13:853-4.
139. Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46:1172-3.
140. Rindone JP, Bryan G 2d. Phenytoin toxicity associated with ticlopidine administration [Letter]. Arch Intern Med. 1996;156:1113.
141. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation. 1996;94:906-10.
142. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. Randomized trial of an oral platelet glycoprotein Ilb/Illa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998;97: 340-9.